The event-free survival rate (EFS) of childhood acute T-lymphocytic leukemia (T-ALL) was significantly lower than that of acute B-lymphocytic leukemia (B-ALL), and the risk of induction failure, early death, and recurrence of childhood T-ALL was significantly higher than that of B-ALL. In recent years, various collaborative groups have continuously adjusted treatment options including using dexamethasone instead of prednisone, applying high-dose methotrexate, monitoring MRD levels, and applying targeted drugs, which have greatly improved the clinical prognosis of childhood T-ALL. This article summarizes the proposals and results of different collaborative groups' treatments of childhood T-ALL.